BACKGROUND: Deranged energy metabolism contributes to the pathophysiology of heart failure (HF). Recent studies showed diminished free fatty acid (FFA) oxidation in experimental HF models with a shift towards oxidation of ketone bodies. However, conflicting clinical data on FFA metabolism and limited knowledge on ketone body metabolism in human HF mandate additional metabolic profiling studies. We, therefore, investigated cardiac uptake of FFAs and ketone bodies (β-hydroxybutyrate and acetoacetate) in patients with HF with reduced ejection fraction (HFrEF) or with aortic stenosis (AS)-induced left ventricular hypertrophy. We hypothesized that FFA oxidation is impaired in HFrEF and in AS and results in decreased concentrations of free carnitine, the necessary carrier for mitochondrial entry of activated FFAs, and in accumulation of metabolic intermediates. METHODS AND RESULTS: We collected arterial and coronary sinus blood samples in patients with HFrEF (n=15), in AS patients with preserved systolic function (n=15), and in control patients (n=15). Plasma concentration gradients across the heart show significantly greater uptake of ketone bodies in patients with HFrEF than in controls. Patients with AS show significantly increased uptake of β-hydroxybutyrate and FFAs. Free carnitine concentration and concentration gradients of intermediates of FFA oxidation were comparable between groups. CONCLUSIONS: In conclusion, our results show significantly increased cardiac uptake of ketone bodies in patients with stable HFrEF and AS and increased uptake of FFAs in AS compared with control patients. The lack of myocardial release of acyl-carnitine species or change in free carnitine uptake suggests no impairment of FFA oxidation.
BACKGROUND: Deranged energy metabolism contributes to the pathophysiology of heart failure (HF). Recent studies showed diminished free fatty acid (FFA) oxidation in experimental HF models with a shift towards oxidation of ketone bodies. However, conflicting clinical data on FFA metabolism and limited knowledge on ketone body metabolism in human HF mandate additional metabolic profiling studies. We, therefore, investigated cardiac uptake of FFAs and ketone bodies (β-hydroxybutyrate and acetoacetate) in patients with HF with reduced ejection fraction (HFrEF) or with aortic stenosis (AS)-induced left ventricular hypertrophy. We hypothesized that FFA oxidation is impaired in HFrEF and in AS and results in decreased concentrations of free carnitine, the necessary carrier for mitochondrial entry of activated FFAs, and in accumulation of metabolic intermediates. METHODS AND RESULTS: We collected arterial and coronary sinus blood samples in patients with HFrEF (n=15), in AS patients with preserved systolic function (n=15), and in control patients (n=15). Plasma concentration gradients across the heart show significantly greater uptake of ketone bodies in patients with HFrEF than in controls. Patients with AS show significantly increased uptake of β-hydroxybutyrate and FFAs. Free carnitine concentration and concentration gradients of intermediates of FFA oxidation were comparable between groups. CONCLUSIONS: In conclusion, our results show significantly increased cardiac uptake of ketone bodies in patients with stable HFrEF and AS and increased uptake of FFAs in AS compared with control patients. The lack of myocardial release of acyl-carnitine species or change in free carnitine uptake suggests no impairment of FFA oxidation.
Authors: Kim L Ho; Liyan Zhang; Cory Wagg; Rami Al Batran; Keshav Gopal; Jody Levasseur; Teresa Leone; Jason R B Dyck; John R Ussher; Deborah M Muoio; Daniel P Kelly; Gary D Lopaschuk Journal: Cardiovasc Res Date: 2019-09-01 Impact factor: 10.787
Authors: Annemarijne R J Veenvliet; Mark R Garrelfs; Floris E A Udink Ten Cate; Sacha Ferdinandusse; Simone Denis; Sabine A Fuchs; Marit Schwantje; Rosa Geurtzen; Annemiek M J van Wegberg; Marleen C D G Huigen; Leo A J Kluijtmans; Ronald J A Wanders; Terry G J Derks; Lonneke de Boer; Riekelt H Houtkooper; Maaike C de Vries; Clara D M van Karnebeek Journal: Mol Genet Metab Rep Date: 2022-05-04
Authors: Sarah O Nomura; Amy B Karger; Natalie L Weir; Joao A C Lima; George Thanassoulis; Michael Y Tsai Journal: J Clin Lipidol Date: 2021-05-31 Impact factor: 5.365
Authors: Jose L Flores-Guerrero; Berend Daan Westenbrink; Margery A Connelly; James D Otvos; Dion Groothof; Irina Shalaurova; Erwin Garcia; Gerjan Navis; Rudolf A de Boer; Stephan J L Bakker; Robin P F Dullaart Journal: Eur J Clin Invest Date: 2020-12-18 Impact factor: 4.686